Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
复制标题
DOI：
10.1136/ard.2007.083071
复制
发表时间：
2009-01-01
影响因子：
27.4
通讯作者：
Brouwers, J. R. B. J.
中科院分区：
文献类型：
--
作者：
Reinders, M. K.;van Roon, E. N.;Brouwers, J. R. B. J.
目的：探讨别嘌呤醇作为抗高尿酸血症治疗痛风的首选药物的疗效和耐受性，并比较苯溴马隆和丙磺舒作为第二选择treatment.Methods的疗效和耐受性：前瞻性，多中心，开放标签，两个阶段的随机对照试验在痛风患者肾功能正常。入组患者接受300 mg别嘌呤醇治疗2个月（第1阶段）。不能耐受别嘌呤醇或未达到目标血清尿酸盐浓度（sUr）的患者
Objectives: To investigate the efficacy and tolerability of allopurinol as the first-choice antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of benzbromarone and probenecid as second-choice treatment.Methods: Prospective, multicentre, open-label, two-stage randomised controlled trial in gout patients with normal renal function. Enrolled patients were given 300 mg allopurinol for 2 months (stage 1). Those patients who could not tolerate allopurinol or who did not attain the target serum urate concentration (sUr)